These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
395 related items for PubMed ID: 11599646
1. Compliance with antidepressants in a primary care setting, 2: the influence of gender and type of impairment. Demyttenaere K, Enzlin P, Dewé W, Boulanger B, De Bie J, De Troyer W, Mesters P. J Clin Psychiatry; 2001; 62 Suppl 22():34-7. PubMed ID: 11599646 [Abstract] [Full Text] [Related]
2. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. Demyttenaere K, Enzlin P, Dewé W, Boulanger B, De Bie J, De Troyer W, Mesters P. J Clin Psychiatry; 2001; 62 Suppl 22():30-3. PubMed ID: 11599645 [Abstract] [Full Text] [Related]
3. [Antidepressants consumption in the global population in France]. Olié JP, Elomari F, Spadone C, Lépine JP. Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542 [Abstract] [Full Text] [Related]
4. Treating depressed primary care patients improves their physical, mental, and social functioning. Coulehan JL, Schulberg HC, Block MR, Madonia MJ, Rodriguez E. Arch Intern Med; 1997 May 26; 157(10):1113-20. PubMed ID: 9164377 [Abstract] [Full Text] [Related]
5. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city]. Mouchabac S, Ferreri M, Cabanac F, Bitton M. Encephale; 2003 May 26; 29(5):438-44. PubMed ID: 14615693 [Abstract] [Full Text] [Related]
7. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women. Pae CU, Mandelli L, Han C, Ham BJ, Masand PS, Patkar AA, Steffens DC, De Ronchi D, Serretti A. Neuro Endocrinol Lett; 2008 Aug 26; 29(4):500-6. PubMed ID: 18766158 [Abstract] [Full Text] [Related]
8. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O'Reardon JP, Lovett ML, Young PR, Haman KL, Freeman BB, Gallop R. Arch Gen Psychiatry; 2005 Apr 26; 62(4):417-22. PubMed ID: 15809409 [Abstract] [Full Text] [Related]
11. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME. J Psychiatr Res; 2008 Jan 26; 42(1):22-34. PubMed ID: 17445831 [Abstract] [Full Text] [Related]
13. [Relationships between insight and medication adherence in subjects with psychosis]. Droulout T, Liraud F, Verdoux H. Encephale; 2003 Jan 26; 29(5):430-7. PubMed ID: 14615692 [Abstract] [Full Text] [Related]
17. [The association between disability and residual symptoms in depressive patients: a 3-month follow-up]. Ozyüksel B, Uluğ B. Turk Psikiyatri Derg; 2007 Aug 26; 18(4):323-32. PubMed ID: 18066723 [Abstract] [Full Text] [Related]
18. Confounding by severity and indication in observational studies of antidepressant effectiveness. Patten SB. Can J Clin Pharmacol; 2008 Aug 26; 15(2):e367-71. PubMed ID: 18840922 [Abstract] [Full Text] [Related]
19. Determinants of functional disability and social adjustment in major depressive disorder: a prospective study. Rytsälä HJ, Melartin TK, Leskelä US, Lestelä-Mielonen PS, Sokero TP, Isometsä ET. J Nerv Ment Dis; 2006 Aug 26; 194(8):570-6. PubMed ID: 16909064 [Abstract] [Full Text] [Related]